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Background. Charcot Marie Tooth disease (CMT) affects one in 
2500 people. Genetic testing is often pursued for family plan-
ning purposes, natural history studies and for entry into clinical 
trials. However, identifying the genetic cause of CMT can be 
expensive and confusing to patients and physicians due to locus 
heterogeneity. 
Methods. We analyzed data from more than 1000 of our patients 
to identify distinguishing features in various subtypes of CMT. 
Data from clinical phenotypes, neurophysiology, family history, 
and prevalence was combined to create algorithms that can be 
used to direct genetic testing for patients with CMT.
Findings. The largest group of patients in our clinic have slow 
motor nerve conduction velocities (MNCV) in the upper extremi-
ties. Approximately 88% of patients in this group have CMT1A. 
Those  who  had  intermediate  MNCV  had  primarily  CMT1X 
(52.8%)  or  CMT1B  (27.8%).  Patients  with  very  slow  MNCV 
and delayed walking were very likely to have CMT1A (68%) or 
CMT1B (32%). No patients with CMT1B and very slow MNCV 
walked before 15 months of age. Patients with CMT2A form our 
largest group of patients with axonal forms of CMT.
Interpretation. Combining features of the phenotypic and physi-
ology groups allowed us to identify patients who were highly 
likely to have specific subtypes of CMT. Based on these results, 
we created a series of algorithms to guide testing. A more detailed 
review of this data is published in Annals of Neurology (1).
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Charcot-Marie-Tooth disease (CMT) is the eponym 
for inherited peripheral neuropathy (2, 3). It is a genetic 
heterogeneous  condition  with  more  than  30  causative 
genes and more than 44 loci identified (http://www.mol-
gen.ua.ac.be/CMTMutations/Mutations/MutByGene.
cfm). CMT is classified into subtypes based on the pattern 
of inheritance and the electrophysiology. Autosomal dom-
inant (AD) demyelinating (CMT1), AD axonal (CMT2), 
autosomal  recessive  and  X-linked  (CMTX)  forms  of 
CMT exist. The large number of CMT causing genes is 
often challenging for clinicians and patients when trying 
to determine the underlying genetic diagnosis. There is 
little information available to guide which gene to test 
and testing a patient for mutations in all commercially 
available CMT genes is not cost effective. Nevertheless, 
family planning and prognosis often require an accurate 
genetic diagnosis and current treatment trials depend on 
knowing the genetic cause of a patient’s CMT even if no 
cures are presently available. 
Recently, a practice parameter guideline was pub-
lished simultaneously in Neurology, Muscle and Nerve 
and PMR that also addressed the issue of genetic testing 
for  CMT (4-6). The  practice  parameter  guideline  pro-
posed an algorithm based on the prevalence of particular 
genetic types of CMT in the literature, whether MNCV 
were < 38 m/s, and whether or not there was a family his-
tory of neuropathy (4-6). The algorithm was an important 
advance in how to focus genetic testing for CMT. Howev-
er, by incorporating phenotypic as well as more specific 
neurophysiologic data we now believe that we can further 
improve diagnostic yields of genetic testing for CMT. To 
assess this we analyzed data from 1024 of our patients to 
identify distinguishing clinical and physiological features 
of the subtypes that could be used to direct genetic testing 
for patients with CMT. We developed an algorithm based 
on clinical phenotypes, neurophysiology, family history 
data, and prevalence that we propose as a guide to help 
focus genetic testing for various forms of CMT.
To investigate whether combining phenotypic data 
with physiology further improved our ability to predict 
an accurate genetic diagnosis, patients were categorized 
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Figure 1. Algorithm to guide genetic testing for CMT in patients with slow ulnar motor nerve conduction velocities. This 
algorithm is designed to be a general guide and is not intended to encompass every potential clinical scenario nor all 
possible genetic etiologies. Dup= duplication; Seq=sequencing.Genetic testing for CMT
111
into groups based on motor nerve conduction velocities 
and age of onset. Results were used to create algorithms 
for testing. 
In  terms  of  MNCVs  affected  patients  were  cat-
egorized into four groups: (1) those with normal MNCV 
(> 45 m/sec); (2) those with mild or “intermediate slow-
ing (35 < and ≤ 45 m/sec); (3) those with slow MNCV 
(15 < and ≤ 35 m/sec) and those with very slow MNCV 
(≤ 15 m/sec). Patients with CMT clustered into three broad 
phenotypic groups based on age of onset. The first group 
we have characterized as the “classical phenotype”, based 
on the descriptions of Harding and Thomas (7, 8). Affected 
patients with a classical phenotype begin walking on time, 
usually by a year to 15 months of age, and develop weak-
ness or sensory loss during the first two decades of life. 
Impairment slowly increases thereafter, and rarely do pa-
tients require ambulation aids beyond ankle foot orthotics 
(AFOs) (9, 10). The second phenotype we define as infan-
tile onset in which patients do not begin walking until they 
are at least 15 months of age. These patients are often se-
verely affected and many required walkers or wheel-chairs 
for ambulation by 20 years of age. The third phenotype is 
defined as adult onset, in which patients do not develop 
symptoms of CMT until adulthood. 
Slow MNCV (15-35 m/s) (Fig. 1)
The largest group of patients in our clinic began have 
slow MNCV in the upper extremities between 15 and 35 
m/s. Approximately 88% of this group will have CMT1A 
and we propose to initially test ONLY for the CMT1A 
causing duplication in these patients. Screening for CM-
T1A should commence irrespective of whether there is a 
positive family history, as approximately 10% of CMT1A 
cases present with apparently de novo mutations (11). Ad-
ditional testing will be pursued only if the patient does not 
have CMT1A. In this event, we propose first ascertaining 
whether there is a family history of male-to-male trans-
mission (father and son affected), since CMT1X is the 
next most common form of CMT in this group based on 
results from our clinic. Only if this testing is negative or if 
there is male-to-male transmission in the pedigree should 
testing proceed for an unusual presentation of CMT1B, 
then CMT1E or other cause of dominantly inherited de-
myelinating neuropathy. In the absence of consanguinity, 
it is predicted that recessive forms of CMT will occur in 
at most 10% of our patients (12). Therefore we propose 
to only test for AR forms when the family history clearly 
suggests this inheritance pattern (multiple affected sib-
lings with no parent, child, or other family members af-
fected)  or  when  the  dominant  forms  of  demyelinating 
neuropathies have been excluded. In the rare cases with 
a clear AD family history, we suggest next undertaking 
research testing to identify novel CMT causing genes.
Severely slow MNCV ( ≤ 15 m/s) (Fig. 2)
For those with severely slow MNCV ( ≤ 15 m/s) ge-
netic testing should be guided by the age of onset. Many 
patients in this group did not begin walking independ-
ently until after 15 months of age. These patients were 
very likely to have CMT1A (68%) or CMT1B (32%). 
Accordingly, we propose to begin testing for the PMP22 
duplication or mutations in the MPZ gene for all patients 
in this category. 
For patients with very slow MNCV ( ≤ 15 m/s) who 
began  walking  before  15  months  we  propose  to  be-
gin testing for only CMT1A. None of our patients with 
CMT1B and MNCV ≤ 15 m/s walked before 15 months 
of age. If this testing is negative, the next most common 
cause of CMT in our clinic population of patients with 
very slow MNCV is CMT1B. Because AD neuropathy 
is much more frequent than AR neuropathy in our clinic 
population, we again propose continuing with AD disor-
ders, even if there is no obvious family history of CMT. If 
there is no PMP22 duplication and if MPZ sequencing is 
normal we suggest sequencing PMP22 (CMT1E), a less 
frequent cause of this presentation. Only if these tests are 
negative should testing proceed to CMT1C and CMT1D, 
very rare forms of CMT1 in our patient group. If testing 
for these is also negative, the presence or absence of an 
affected parent or child can be used to determine whether 
to next test for AR disorders or whether research testing 
for novel genes is more appropriate. 
CMT with Intermediate MNCV (35-45 m/s) (Fig. 3)
Patients  with  identified  genetic  causes  of  CMT 
who had intermediate MNCV (35-45 m/s) had prima-
rily CMT1X (52.8%) or CMT1B (27.8%). For patients 
with intermediate MNCV, the first step is to determine 
whether the phenotype is classical or adult onset and then 
whether there is evidence of male-to-male transmission. 
For patients with intermediate conductions and a classi-
cal phenotype, the first test should be for GJB1 mutations 
(CMT1X) (78%). It is important to note that testing for 
X-linked forms of CMT should only be pursued in the 
absence of male-to-male transmission. If this testing is 
negative, testing should proceed to MPZ mutations. Alter-
natively, if there is male-to-male transmission, testing for 
CMT1B should occur first since the inheritance pattern 
would formally exclude CMT1X. 
If  patients  with  intermediate  MNCV  first  devel-
op  symptoms  in  adulthood,  testing  should  begin  with 
CMT1B, as this is most likely according to our results. 
As no patients with CMT1A had intermediate conduc-
tion velocities, testing for a PMP22 duplication would 
not be warranted. If all testing is negative, the presence 
or absence of an affected parent or child can be used to L.J. Miller et al.
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Figure 2. Algorithm to guide genetic testing for CMT in patients with very slow ulnar motor nerve conduction velocities. 
This algorithm is designed to be a general guide and is not intended to encompass every potential clinical scenario nor 
all possible genetic etiologies. Dup= duplication; Seq=sequencing.Genetic testing for CMT
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Figure 3. Algorithm to guide genetic testing for CMT in patients with intermediate ulnar motor nerve conduction veloci-
ties. This algorithm is designed to be a general guide and is not intended to encompass every potential clinical scenario 
nor all possible genetic etiologies.L.J. Miller et al.
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determine whether to next test for rare or AR disorders 
or whether research testing for novel genes is more ap-
propriate. Some rare genes for the dominant intermedi-
ate forms of CMT include DNM2 (DI-CMTB) and YARS 
(DI-CMTC)  mutations. These  are  not  included  on  the 
flow diagram because there are no genetically confirmed 
cases of these in our clinic. However, it is possible that 
they will make up a clinically significant part of the CMT 
population in the future, and these flow charts can be al-
tered to reflect that. Patients with HNPP were identified 
in the intermediate NCV group with childhood and adult 
onset of symptoms. This disorder was not included in Fig-
ure 3 (or Fig. 4) because of its characteristic presentation 
of focal episodes of weakness or sensory loss and focal 
slowing of MNCV that distinguish it from other forms of 
CMT. These clinical and physiological findings should, 
by themselves, suggest testing for HNPP (13, 14).
Targeted testing for normal or unobtainable NCV (Fig. 4)
Patients with CMT2A were frequently severely af-
fected in infancy and childhood to the extent that their 
CMAP amplitudes and NCV were unobtainable by test-
ing in the upper extremities, Since patients with CMT2A 
form our largest group of patients with CMT2 (Feely, 
submitted) we propose to test patients with severe ax-
onal neuropathies in childhood initially for mutations in 
MFN2, the cause of CMT2A. The other two common 
forms of CMT that presented with normal MNCV in the 
arms were CMT1X (particularly women), and CMT1B. 
Testing for CMT1B and CMT1X would be reasonable 
for late onset patients with normal MNCV unless there 
was male-to-male transmission in the pedigree, in which 
case only CMT1B is appropriate. Testing for all other 
forms of CMT2 would be far less likely to be successful 
and would be reserved for those patients who were neg-
ative for CMT2A, CMT1X and CMT1B. In our clinic, 
we have four patients with mutations in NEFL causing 
CMT2E, five patients with a single (identical) mutation 
in GDAP1 causing CMT2K, and three patients with mu-
tations in GARS causing CMT2D. Other potential caus-
es of CMT2 including mutations in HSP22 (CMT2L) 
or HSP27 (CMT2F) might then be considered. Patients 
with RAB7 (CMT2B) and SPTLC1 (HSN1) mutations 
have  predominantly  sensory  phenotypes,  and  patients 
with  GARS  (CMT2D)  or  BSCL2  (Silver  syndrome) 
mutations often have relatively pure motor syndromes. 
Moreover, patients with CMT2D often note hand im-
pairment prior to leg impairment that is unusual for pa-
tients with CMT. Thus in CMT2 we propose to use these 
specific phenotypes to direct additional genetic testing 
after initial negative testing. It may be necessary to per-
form nerve conductions on proximal nerves if CMAP 
and SNAP potentials are unobtainable distally.
Before pursuing genetic testing we feel it is impor-
tant to consider that not every patient with a genetic neu-
ropathy wants or needs genetic testing (15). We believe 
that the ultimate decision to undergo genetic testing rests 
with the patient or the patient’s parents if a symptomatic 
child is under 18 years of age. Reasons that patients give 
for obtaining testing include identifying the inheritance 
pattern of their CMT, making family planning decisions, 
and obtaining knowledge about the cause and natural his-
tory of their form of CMT. Natural history data is avail-
able for some forms of CMT such as CMT1A (10) and 
CMT1X (16), which can provide guidance for progno-
sis, recognizing that there can be phenotypic variability 
in these subtypes. Patients with other forms of CMT fre-
quently choose to undergo genetic testing to contribute 
to the natural history data collection for other patients 
with the same subtype. There are also reasons why pa-
tients do not want genetic testing. These include the high 
costs of commercial testing and fears of discrimination 
in the workplace or in obtaining health insurance. Since 
there are currently no medications to reverse any form 
of CMT, many patients decide against testing since their 
therapies will not depend on the results. We maintain that 
it is always the patient’s decision whether or not to pursue 
genetic testing.
Once a genetic diagnosis has been made in a patient, 
other family members usually do not need genetic testing 
and can be diagnosed by clinical evaluation with neuro-
physiology. We do not typically test patients for multiple 
genetic causes of CMT simultaneously. It is our current 
policy to only consider genetic testing clinically affected 
family members if their phenotype is atypical for the type 
of CMT in the family. In addition, we do not test asymp-
tomatic minors with a family history of CMT, either by 
electrophysiology or genetic testing, due to the chance 
for increased psychological harm to the child (17). We 
do routinely perform limited nerve conduction studies, 
though not needle EMG, on symptomatic children with 
CMT. Since nerve conduction changes, including slow-
ing, are often uniform and detectable in early childhood 
in CMT (18), testing of a single nerve is often adequate 
to guide genetic testing or determine whether a sympto-
matic child is affected in a family with CMT.
In summary, patients with inherited neuropathies can 
serve as models of their own disease if their phenotypes 
are carefully analyzed and their genotypes characterized. 
Molecular mechanisms of demyelination, axonal loss and 
axo-glial interactions can thus be investigated and ration-
al therapies can be developed, not only for CMT but for 
related neurodegenerative disorders. However genotyp-
ing of families is essential for this approach, is confus-
ing to patients and physicians and is very expensive to 
undertake commercially or in research laboratories. We Genetic testing for CMT
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Figure 4.  Algorithm to guide genetic testing for CMT in patients with normal ulnar motor nerve conduction velocities. 
This algorithm is designed to be a general guide and is not intended to encompass every potential clinical scenario nor 
all possible genetic etiologies.L.J. Miller et al.
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have developed what we believe is a focused approach to 
testing based on phenotype, physiology and prevalence 
that we hope will prove useful in our clinic and to others 
who care for patients with inherited neuropathies.
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